HIV-infected patients starting highly active antiretroviral therapy (HAART) in developing countries have increased mortality rates in the first months on therapy compared with those in developed countries, according to a paper in this week's issue of The Lancet. The authors state that early diagnosis and assessment of treatment eligibility, coupled with free provision of HAART, might reduce this excess mortality.
HAART has substantially improved the prognosis of HIV-infected patients who have access to these drugs. HAART is being scaled up in developing countries but several factors could limit the effectiveness of the therapy in resource-poor settings.
In this study the researchers compared the ART-LINC Collaboration--a network of 18 HAART programmes in Africa, Asia, and South America--with a similar network of 12 HAART programmes in Europe and North America. They found that mortality was higher in low-income settings than in high-income settings. Patients in low-income countries had lower CD4 cell counts (indicating an increased risk of infection) and more advanced clinical disease when they started treatment. However, the authors state that this only partly explains the higher mortality. They believe accompanying illnesses (comorbidities) such as tuberculosis that are present in many low-income settings may have increased mortality. They also found that the provision of treatment free of charge in low-income settings was strongly associated with lower mortality.
Author Dr Matthias Egger (University of Berne, Switzerland) concludes: "Antiretroviral therapy is feasible and effective in low income settings, but, compared with industrialized countries, mortality is high in the first months. Eligibility for antiretroviral treatment and the need for treatment of tuberculosis should be determined earlier, and HAART should be started before serious comorbidities develop."
In an accompanying Editorial, The Lancet comments: "The start of thPage: 1 2 Related medicine news :1
Contact: Joe Santangelo
. Study shows interruption of antiretroviral therapy increases risk of disease and death2
. No advantage for four-drug antiretroviral regimen vs. three-drug for initial treatment of HIV-13
. Sub-Saharan Africans with HIV may achieve favorable levels of antiretroviral therapy adherence4
. Saving antiretroviral treatment in long-term HIV-positive patients5
. Access to antiretrovirals unlikely to reduce HIV infection rates6
. Study sets new gold standard for initial antiretroviral treatment of HIV infection7
. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy8
. HIV mortality in India drops with introduction of generic antiretroviral therapy9
. Highly active antiretrovirals for HIV can substantially reduce rates of AIDS10
. Chemotherapy with bevacizumab increases risk of blood clots in arteries11
. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone